Sabra Health Care REIT (SBRA) Insider Katzmann Buys 8,310 Shares
Lynne Katzmann's recent purchase of shares comes as other insiders also buy into Sabra Health Care REIT.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lynne Katzmann bought 8,310 shares of Sabra Health Care REIT, Inc. ($SBRA) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SBRA is up 5.8% after 1 week, up 11.4% after 1 month and up 8.8% to date (from the $17.78 close on Jun 17, 2026).
SBRA
Sabra Health Care REIT, Inc.
Key Points
- Lynne Katzmann bought 8,310 shares of Sabra Health Care REIT on June 17, 2026, valued at about $150,000 based on a share price of $18.12.
- The stock is currently trading below its 52-week high of $22.77, having closed at $19.74 the previous day.
- Analysts maintain a consensus rating of 'buy' for Sabra Health Care REIT, with a mean price target of $22.79.
Get $SBRA trade alerts by text
We text you when insiders, Congress or big funds trade $SBRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sabra Health Care REIT, Inc. alert may contain errors. Disclosures
Katzmann's Insider Purchase
Lynne Katzmann bought 8,310 shares of Sabra Health Care REIT, Inc. (SBRA) on June 17, 2026. The shares were purchased at a price of $18.12 each, bringing the total value of the transaction to about $150,000. This purchase reflects Katzmann's confidence in the company's prospects.
Other Insiders Also Buying
Katzmann wasn't alone in this buying spree. Five other insiders also acquired 8,310 shares each on the same day, including Craig Barbarosh, Jeffrey Malehorn, Michael Foster, Catherine Cusack, and Ann Kono. This coordinated activity suggests a strong belief among the leadership in the company's future performance.
How Sabra Health Care REIT, Inc. Stock Has Traded
Sabra Health Care REIT's stock closed at $19.74 before Katzmann's purchase, which is below its 52-week high of $22.77. The stock has been trading near its 200-day moving average of $19.93, indicating some stability despite recent fluctuations. Investors may be watching to see if this insider buying leads to a positive shift in stock performance.
Analysts Set New Price Targets
On October 13, 2026, UBS maintained a 'Neutral' rating on Sabra Health Care REIT with a price target of $20, down from $21. Barclays also maintained an 'Equal-Weight' rating, lowering its target from $23 to $21. The consensus among analysts remains positive, with a mean price target of $22.79 based on 14 opinions.
What Sabra Health Care REIT, Inc. Does
Sabra Health Care REIT, Inc. is a real estate investment trust that invests in properties serving the healthcare industry. The company operates across the U.S. and Canada, focusing on facilities that support health services. The recent insider purchases may indicate a belief in the company's growth potential.
What's Next for Sabra Health Care REIT, Inc.
Investors will be looking for further developments, especially with the next earnings report scheduled for November 4, 2026. The recent insider trading activity, particularly on June 17, reflects a potentially bullish outlook from the company's leadership. As always, remember that these filings reflect past transactions and may not indicate current positions.
Related Filing Alerts
Source: Lynne Katzmann's Form 4 filing on $SBRA (Jun 17, 2026). Find the original filing: SBRA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts